Novo Nordisk has announced new clinical trial data that further underlines the benefits offered by the type 2 diabetes therapy semaglutide.
Data from the SUSTAIN 7 clinical trial has demonstrated that people with type 2 diabetes treated with once-weekly semaglutide experienced superior glucose control and weight loss compared to an alternative therapy.
“Novo Nordisk has reported new clinical data showing the benefits of semaglutide in terms of glucose control and weight loss in people with type 2 diabetes.“
Semaglutide was also associated with a safe and well-tolerated profile, consistent with results from the broader SUSTAIN study programme, with premature treatment discontinuation due to adverse events shown to be less than ten percent across all treatment groups.
The SUSTAIN study programme for semaglutide comprises seven phase III global clinical trials, including a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes.
Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "The superior glucose control and weight loss achieved with semaglutide compared to dulaglutide in this trial reinforces the unprecedented results observed in the entire SUSTAIN programme."
Semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical